Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Siegel

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|June 13, 2025
Quality principles in Phase I dose escalation designJonathan M Siegel
Pharmaceutical Statistics|March 29, 2024
Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidanceJonathan M Siegel, Hans-Jochen Weber, Stefan Englert, et al.
The American Journal of Managed Care|June 24, 2003
Drivers of expenditure growth in outpatient care servicesKeith Hearle, Lane Koenig, Robin Rudowitz, et al.
The American Journal of Managed Care|June 24, 2003
Drivers of healthcare expenditures associated with physician servicesLane Koenig, Jonathan M Siegel, Allen Dobson, et al.
Health Affairs (Project Hope)|December 3, 2003
Estimating the mission-related costs of teaching hospitalsLane Koenig, Allen Dobson, Silver Ho, et al.
Journal of Substance Abuse Treatment|March 31, 2005
Economic benefits of substance abuse treatment: findings from Cuyahoga County, OhioLane Koenig, Jonathan M Siegel, Henrick Harwood, et al.
Scientific Reports|June 27, 2024
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesotheliomaCharles S Cleeland, Karen N Keating, Brian Cuffel, et al.
Breast Cancer Research and Treatment|December 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trialsHope S Rugo, Catherine H Van Poznak, Patrick Neven, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|June 13, 2025
Quality principles in Phase I dose escalation designJonathan M Siegel
Pharmaceutical Statistics|March 29, 2024
Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidanceJonathan M Siegel, Hans-Jochen Weber, Stefan Englert, et al.
The American Journal of Managed Care|June 24, 2003
Drivers of expenditure growth in outpatient care servicesKeith Hearle, Lane Koenig, Robin Rudowitz, et al.
The American Journal of Managed Care|June 24, 2003
Drivers of healthcare expenditures associated with physician servicesLane Koenig, Jonathan M Siegel, Allen Dobson, et al.
Health Affairs (Project Hope)|December 3, 2003
Estimating the mission-related costs of teaching hospitalsLane Koenig, Allen Dobson, Silver Ho, et al.
Journal of Substance Abuse Treatment|March 31, 2005
Economic benefits of substance abuse treatment: findings from Cuyahoga County, OhioLane Koenig, Jonathan M Siegel, Henrick Harwood, et al.
Scientific Reports|June 27, 2024
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesotheliomaCharles S Cleeland, Karen N Keating, Brian Cuffel, et al.
Breast Cancer Research and Treatment|December 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trialsHope S Rugo, Catherine H Van Poznak, Patrick Neven, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Pageof 1